関連する実験動画
Updated: Jun 2, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
ピルフェニドンのイディオパシー性肺線維症 (CAPACITY) 患者への投与: 2つのランダム化試験
Paul W Noble1, Carlo Albera, Williamson Z Bradford
1Duke University School of Medicine, Durham, NC 27710, USA. paul.noble@duke.edu
Lancet (London, England)
|May 17, 2011
まとめ
抗線維薬であるピルフェニドンは,イディオパシー性肺線維症の患者で研究されました. それは,好ましい利益リスクプロファイルを示し,肺機能の低下と死亡率を低減し,実行可能な治療選択肢にしました.
科学分野:
- 肺内科 肺内科 肺内科
- 薬理学 薬理学とは
- クリニック・トライアル 臨床試験
背景:
- Idiopathic pulmonary fibrosis (IPF) は進行性で致命的な肺疾患であり,避けられない肺機能低下が特徴です.
- CAPACITYプログラム (研究004および006) は,IPFの進行を遅らせるピルフェニドンの有効性を確認することを目的とした.
研究 の 目的:
- idiopathic pulmonary fibrosisの患者における口服ピルフェニドンの有効性と安全性を評価する.
- IPF患者における肺機能の悪化を軽減するピルフェニドンの能力を確認する.
主な方法:
- 40歳から80歳のIPF患者779人を対象とした2つの同時進行したランダム化プラセボ対照試験 (CAPACITY研究004および006) が実施されました.
- 患者は口服ピルフェニドン (2403 mg/日または1197 mg/日) またはプラセボを少なくとも72週間投与された.
- プライマリエンドポイントは,第72週に予測された強制生命能力 (FVC) の割合の変化であり,治療意図分析が行われました.
主要な成果:
- 試験004では,ピルフェニドン2403 mg/日がプラセボと比較してFVCの減少を有意に減少させました (4.4%の差異,p=0.001), ≥10%の減少 (20%対35%) を経験した患者数が少なくなりました.
- 試験006は72週にFVCの変化の統計的に有意な差異を示さなかったが,ピルフェニドンは48週まで一貫した効果を示した.
- Pirfenidone 2403 mg/dayは,有害事象 (吐き気,消化不良,発疹) の増加と関連していたが,プラセボと比較して全体およびIPFに関連する死亡者は少なかった.
結論:
- ピルフェニドンは,イディオパシー性肺線維症の治療に有利な利益リスクプロファイルを示しています.
- ピルフェニドンは,イディオパシー性肺線維症と診断された患者にとって適切な治療法です.
関連する概念動画
01:25Pulmonary Function Tests
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...